Angiotensin-converting enzyme 2 and hepatic SARS-CoV-2 infection:Regulation,association,and therapeutic implications  

作　　者：Yu-Wei Luo Ai-Long Huang Kai-Fu Tang 

机构地区：[1]Key Laboratory of Molecular Biology on Infectious Disease,Ministry of Education,Chongqing Medical University,Chongqing 400016,China

出　　处：《World Journal of Gastroenterology》2025年第6期8-13,共6页世界胃肠病学杂志(英文)

基　　金：Supported by National Natural Science Foundation of China,No.82172915,No.81972648,and No.81773011;Chongqing Medical University Program for Youth Innovation in Future Medicine,No.W0084;Science and Technology Innovation Project of Chongqing Medical University;and Chongqing Postdoctoral Science Foundation,No.CSTB2023NSCQ-BHX0134.

摘　　要：Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)enters host cells via the angiotensin-converting enzyme 2(ACE2)receptor.Mounting evidence has indicated the presence of hepatic SARS-CoV-2 infection and liver injury in pa-tients with coronavirus disease 2019(COVID-19).Understanding the mechanisms of hepatic SARS-CoV-2 infection is crucial for addressing COVID-19–related liver pathology and developing targeted therapies.This editorial discusses the signi-ficance of ACE2 in hepatic SARS-CoV-2 infection,drawing on the research by Jacobs et al.Their findings indicate that hepatic ACE2 expression,frequency of hepatic SARS-CoV-2 infection,and severity of liver injury are elevated in patients with pre-existing chronic liver diseases.These data suggest that hepatic ACE2 could be a promising therapeutic target for COVID-19.

关 键 词：Hepatic angiotensin-converting enzyme 2 SARS-CoV-2 Liver infection Chronic liver diseases COVID-19 treatment 

分 类 号：R563.1[医药卫生—呼吸系统] R575[医药卫生—内科学]